Search Results - "TIDMARSH, George"

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II by Tumlin, James A., Murugan, Raghavan, Deane, Adam M., Ostermann, Marlies, Busse, Laurence W., Ham, Kealy R., Kashani, Kianoush, Szerlip, Harold M., Prowle, John R., Bihorac, Azra, Finkel, Kevin W., Zarbock, Alexander, Forni, Lui G., Lynch, Shannan J., Jensen, Jeff, Kroll, Stew, Chawla, Lakhmir S., Tidmarsh, George F., Bellomo, Rinaldo

“…OBJECTIVE:Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II…”
Get full text

Broad spectrum vasopressors: a new approach to the initial management of septic shock? by Chawla, Lakhmir S, Ostermann, Marlies, Forni, Lui, Tidmarsh, George F

“…The mainstay of hemodynamic treatment of septic shock is fluid resuscitation followed by vasopressors where fluids alone are insufficient to achieve target…”
Get full text

Angiotensin converting enzyme defects in shock: implications for future therapy by Chawla, Lakhmir S, Chen, Steve, Bellomo, Rinaldo, Tidmarsh, George F

Get full text

Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock. A Clinical Trial by Bellomo, Rinaldo, Forni, Lui G, Busse, Laurence W, McCurdy, Michael T, Ham, Kealy R, Boldt, David W, Hästbacka, Johanna, Khanna, Ashish K, Albertson, Timothy E, Tumlin, James, Storey, Kristine, Handisides, Damian, Tidmarsh, George F, Chawla, Lakhmir S, Ostermann, Marlies

“…Exogenous angiotensin II increases mean arterial pressure in patients with catecholamine-resistant vasodilatory shock (CRVS). We hypothesized that renin…”
Get full text

Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock by Bellomo, Rinaldo, Wunderink, Richard G, Szerlip, Harold, English, Shane W, Busse, Laurence W, Deane, Adam M, Khanna, Ashish K, McCurdy, Michael T, Ostermann, Marlies, Young, Paul J, Handisides, Damian R, Chawla, Lakhmir S, Tidmarsh, George F, Albertson, Timothy E

“…In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to…”
Get full text

LJ000328, a novel ALK2/3 kinase inhibitor, represses hepcidin and significantly improves the phenotype of IRIDA by Belot, Audrey, Gourbeyre, Ophélie, Fay, Alexis, Palin, Anais, Besson-Fournier, Céline, Latour, Chloé, Hopkins, Corey R, Tidmarsh, George F, Coppin, Hélène, Roth, Marie-Paule, Ritter, Matthew R, Hong, Charles C, Meynard, Delphine

Get full text

Therapeutic Opportunities for Hepcidin in Acute Care Medicine by Chawla, Lakhmir S., Beers-Mulroy, Blaire, Tidmarsh, George F.

“…Iron homeostasis is often disrupted in acute disease with an increase in catalytic free iron leading to the formation of reactive oxygen species and subsequent…”
Get full text

Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial by Ham, Kealy R., Boldt, David W., McCurdy, Michael T., Busse, Laurence W., Favory, Raphael, Gong, Michelle N., Khanna, Ashish K., Chock, Stefan N., Zeng, Feng, Chawla, Lakhmir S., Tidmarsh, George F., Ostermann, Marlies

“…Background Early clinical data showed that some patients with vasodilatory shock are responsive to low doses of angiotensin II. The objective of this analysis…”
Get full text

2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo by MASCHEK, Gregory, SAVARAJ, Niramol, PRIEBE, Waldemar, BRAUNSCHWEIGER, Paul, HAMILTON, Kara, TIDMARSH, George F, DE YOUNG, Linda R, LAMPIDIS, Theodore J

“…Slow-growing cell populations located within solid tumors are difficult to target selectively because most cells in normal tissues also have low replication…”
Get full text

Angiotensin II for the Treatment of Vasodilatory Shock by Khanna, Ashish, English, Shane W, Wang, Xueyuan S, Ham, Kealy, Tumlin, James, Szerlip, Harold, Busse, Laurence W, Altaweel, Laith, Albertson, Timothy E, Mackey, Caleb, McCurdy, Michael T, Boldt, David W, Chock, Stefan, Young, Paul J, Krell, Kenneth, Wunderink, Richard G, Ostermann, Marlies, Murugan, Raghavan, Gong, Michelle N, Panwar, Rakshit, Hästbacka, Johanna, Favory, Raphael, Venkatesh, Balasubramanian, Thompson, B. Taylor, Bellomo, Rinaldo, Jensen, Jeffrey, Kroll, Stew, Chawla, Lakhmir S, Tidmarsh, George F, Deane, Adam M

“…Patients with vasodilatory shock were randomly assigned to angiotensin II or placebo. At 3 hours, more patients in the angiotensin II group than in the placebo…”
Get full text

Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): Protocol for a phase III, double-blind, randomised controlled trial by Chawla, Lakhmir S, Russell, James A, Bagshaw, Sean M, Shaw, Andrew D, Goldstein, Stuart L, Fink, Mitchell P, Tidmarsh, George F

“…Objective: Catecholamine-resistant hypotension (CRH) is characterised by inadequate response to standard doses of vasopressors, and increased mortality. Our…”
Get full text

Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells by Ruvolo, Peter P., Ruvolo, Vivian R., Benton, Christopher B., AlRawi, Ahmed, Burks, Jared K., Schober, Wendy, Rolke, James, Tidmarsh, George, Hail, Numsen, Eric Davis, R., Andreeff, Michael

“…Galectin 3 (LGALS3) expression is prognostic for poor survival in acute myeloid leukemia (AML) patients. GCS-100 is a novel galectin inhibitor that may prove…”
Get full text

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine by Ciuleanu, Tudor E, Pavlovsky, Alexander V, Bodoky, Gyorgy, Garin, Avgust M, Langmuir, Virginia K, Kroll, Stewart, Tidmarsh, George T

“…Abstract Purpose There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine. This…”
Get full text

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas by KAMINSKI, Mark S, ZELENETZ, Andrew D, WAHL, Richard L, KNOX, Susan J, VOSE, Julie M, PRESS, Oliver W, SALEH, Mansoor, LEONARD, John, FEHRENBACHER, Louis, LISTER, T. Andrew, STAGG, Robert J, TIDMARSH, George F, KROLL, Stew

“…To evaluate the efficacy and safety of tositumomab and iodine I 131 tositumomab (Bexxar; Corixa Corp, Seattle, WA, and GlaxoSmithKline, Philadelphia, PA) in…”
Get full text

Abbreviated Chemotherapy With Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab for Untreated Follicular Lymphoma by LEONARD, John P, COLEMAN, Morton, KROLL, Stewart, TIDMARSH, George, VALLABHAJOSULA, Shankar, GOLDSMITH, Stanley J, KOSTAKOGLU, Lale, CHADBURN, Amy, CESARMAN, Ethel, FURMAN, Richard R, SCHUSTER, Michael W, NIESVIZKY, Ruben, MUSS, Daniel, FIORE, Jennifer

“…To evaluate the safety and efficacy of a sequential chemotherapy plus radioimmunotherapy (RIT) regimen in previously untreated follicular non-Hodgkin's…”
Get full text

Synthetic Human Angiotensin II in Pediatric Patients With Vasodilatory Shock: A Report on Two Patients by Bailey, Dwight M, Chima, Ranjit S, Tidmarsh, George F, Williams, Mark D

“…Severe sepsis and septic shock continue to be an important problem in children, with hospital mortality rates for pediatric severe sepsis as high as 25%. Two…”
Get full text

Bridging the gap between basic and applied biology: towards preclinical translation by Cagan, Ross L, Justice, Monica J, Tidmarsh, George F

“…To better translate basic research findings into the clinic, we are moving away from the traditional one-gene-one-phenotype model towards the discovery of…”
Get full text

A Novel Alkylating Agent, Glufosfamide, Enhances the Activity of Gemcitabine In Vitro, In Vivo by Ammons, W. Steve, Wang, Jin-Wei, Yang, Zhijian, Tidmarsh, George F., Hoffman, Robert M.

“…Glufosfamide is an alkylating agent consisting of iphosphoramide mustard conjugated to glucose that is currently included in clinical studies of pancreatic…”
Get full text

A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma by Chiorean, Elena G, Dragovich, Tomislav, Hamm, John, Barrios, Carlos H, Gorini, Carlos F, Langmuir, Virginia K, Kroll, Stewart, Jung, Donald T, Tidmarsh, George T, Loehrer, Patrick J

“…A dose-escalation study of glufosfamide plus gemcitabine showed that the combination could be administered safely at full doses. The purpose of this phase II…”
Get full text

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas by VOSE, J. M, WAHL, R. L, SALEH, M, ROHATINER, A. Z, KNOX, S. J, RADFORD, J. A, ZELENETZ, A. D, TIDMARSH, G. F, STAGG, R. J, KAMINSKI, M. S

“…This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with…”
Get full text